Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Common Equity (2016 - 2025)

Historic Common Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $8.3 million.

  • China Pharma Holdings' Common Equity rose 2735.42% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 2735.42%. This contributed to the annual value of $7.7 million for FY2024, which is 393.42% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Common Equity is $8.3 million, which was up 2735.42% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Common Equity registered a high of $8.3 million during Q3 2025, and its lowest value of $2.8 million during Q3 2022.
  • Its 5-year average for Common Equity is $6.2 million, with a median of $6.5 million in 2021.
  • In the last 5 years, China Pharma Holdings' Common Equity crashed by 5864.34% in 2022 and then soared by 11555.68% in 2023.
  • Over the past 5 years, China Pharma Holdings' Common Equity (Quarter) stood at $6.0 million in 2021, then decreased by 28.71% to $4.3 million in 2022, then skyrocketed by 73.77% to $7.5 million in 2023, then rose by 3.93% to $7.7 million in 2024, then rose by 7.31% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $6.5 million for Q2 2025, and $7.0 million during Q1 2025.